Hangzhou Tigermed Consulting (03347): As of June 16, a total of 17.783 million shares of A shares have been repurchased.

20:53 16/06/2026

Tage Pharmaceuticals (03347) announced that as of June 16, 2026, the company repurchased 17.783 million shares through its share repurchase special securities account in the form of centralized bidding trading, accounting for 2.0654% of the company's current total share capital and 2.4100% of the company's current A-share total share capital. The highest transaction price was 39.96 yuan/share, the lowest transaction price was 38.22 yuan/share, and the total transaction amount was 698.9 million yuan (excluding transaction costs). This repurchase is in compliance with the company's share repurchase plan and relevant laws and regulations.

Hangzhou Tigermed Consulting (03347) announced that as of June 16, 2026, the company has repurchased a total of 17.783 million shares through the stock repurchase special securities account in a centralized bidding trading manner, representing 2.0654% of the company's total share capital and 2.4100% of the company's current A-share total share capital. The highest transaction price was 39.96 yuan per share, the lowest transaction price was 38.22 yuan per share, and the total transaction amount was 698.9 million yuan (excluding transaction fees). This repurchase meets the requirements of the company's share repurchase plan and relevant laws and regulations.

LYUE PHARMA (02186) innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has achieved positive results in the Phase II clinical trial for the treatment of delayed onset movement disorders in China.

US Stock Market Move | Qualcomm (QCOM.US) opens up more than 4%, rumored to be in talks to acquire Tenstorrent.

IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.

US Stock Market Move | Qualcomm (QCOM.US) opens up more than 4%, rumored to be in talks to acquire Tenstorrent.

IMMUNEONCO-B (01541) spent HK$592,500 to repurchase 163,200 shares on June 16.